Lipopolysaccharide functions as a vaccine adjuvant but is considered too toxic for clinical use. The major structural element responsible for its toxicity and adjuvant effect is lipid A.

In this report, we present the largest case series of patients developing AK and/or cutaneous SCC during therapy with sorafenib. The mechanism through which sorafenib may be implicated in the ...